Using the biologic license application or new drug application as a basis for the common technical document
1Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. mfoote@amgen.com
Abstract:
With the introduction of the common technical document (CTD), many writers in the biotech and pharmaceutical industries are now required to submit dossiers in this format. The format of the CTD is not extremely difficult from the familiar documents of the Biologic License Application (BLA) or New Drug Application (NDA). The CTD can be mapped to existing areas of the BLA or NDA. The components of the CTD are discussed and references to the current guidance worldwide are provided to assist the writer.
Related Concept Videos
Clinical Trials: Overview
Preclinical Development: Overview
Bioequivalence studies: Biowaivers
Drug Products: Biologics, Biosimilars and Interchangeables
Clinically Relevant Drug Product Specifications: Methods of Establishment
Therapeutic Drug Monitoring: Drug Analysis Methods


